Interleukin-2, Interferon-α and 5-Fluorouracil Immunotherapy for Metastatic Renal Cell Carcinoma: The All Ireland Experience

European Urology

Volumn 45, Issue 5, 2004, Pages 613-619

  O'Brien, M F ^a   Rea, D ^a   Rogers, E ^b   Bredin, H ^c   Butler, M ^a   Grainger, R ^a   McDermott, T E D ^a   Mullins, G ^b   O'Brien, A ^d   Twomey, A ^e   Thornhill, J ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b BON SECOURS HOSPITAL   (Ireland)

^c UNIVERSITY HOSPITAL GALWAY   (Ireland)

^d CRAIGAVON AREA HOSPITAL   (United Kingdom)

^e Mallow General Hospital   (Ireland)

Author keywords

5 Fluorouracil; Interferon ; Interleukin 2; Metastatic; Multicentre administration; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; FLUOROURACIL; INTERLEUKIN 2; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IRELAND; KIDNEY CARCINOMA; LONG TERM CARE; LUNG METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MULTICENTER STUDY; NEPHRECTOMY; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 11144358544     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.11.002     Document Type: Article

References (17)

1. Rabinovitch R.A., Zelefsky M.J., Gaynor J.J., Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. Oncol. 12:1994;206-212.
2. de Kernion J.B., Ramming K.P., Smith R.B. Natural history of metastatic renal carcinoma: a computer analysis. J. Urol. 120:1978;148-152.
3. Yagoda Y. Chemotherapy of renal cell cancer. Semin. Urol. 12:1989;199-206.
4. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R.et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin 2. JAMA. 271:1994;907-913.
5. Atzpodien J., Korfer A., Franks C.R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 335:1990;1509-1512.
6. Stebbing J., Benson C., Eisen T., Pyle L., Smalley K., Bridle H.et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer. 85:2001;953-958.
7. Bleumer I., Beck J., Oosterwijk Mala C., Ullrich S., Mulders F.F.A. A phase I/II trial with chimeric monoclonal antibody WX-G250 in combination with low dose interleukin-2 for patients with metastatic renal cell carcinoma. Eur. Urol. 2:2003;A383.
8. Rogers E., Bredin H., Butler M., Corcoran M., Egan E., Fennelly J.et al. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group. Eur. Urol. 37:2000;261-266.
9. Atzpodien J., Hoffmann R., Franzke M., Stief C., Wandert T., Reitz M. Thirteen-year, long-term efficacy of interferon 2α and interleukin-2 based home therapy in patients with advanced renal cell carcinoma. Cancer. 95:2002;1045-1050.
10. Hanninen E.L., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J. Urol. 155:1996;19-25.
11. Hofmockel G., Langer W., Theiss M., Gruss A., Frohmuller H.G.W. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-α and 5-fluorouracil. J. Urol. 156:1996;18-21.
12. Joffe J.K., Banks R.E., Forbes M.A., Hallam S., Jenkins A., Patel P.M.et al. A phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal cell carcinoma: clinical data and laboratory evidence of protease activation. Br. J. Urol. 77:1996;638-649.
13. Atzpodien J., Kirchner H., Hanninen E.L., Deckert M., Fenner M., Poliwoda H. Interleukin-2 in combination with interferon-α and 5-fluorouracil for metastatic renal cell cancer. Eur. J. Cancer. 29:1993;S6-S8.
14. Mickisch G.H.J., Garin A., van Poppel L., de Prijck L., Sylvester R. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 358:2001;966-970.
15. Flanigan R.C., Salmon S.E., Blumenstein B.A., Bearman S.I., Roy V., McGrath P.C.et al. Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal cell cancer. N. Engl. J. Med. 345:2001;1655-1659.
16. Kattan M.W., Reuter V., Motzer R.J., Katz J., Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J. Urol. 166:2001;63-67.
17. Zisman A., Pantuck A.J., Wieder J., Chao D.H., Dorey F., Said J.W.et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20:2002;4559-4566.